Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease.

Related Articles Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Singh S, Fumery M, Sandborn WJ, Murad MH Abstract BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe Crohn’s disease (CD). AIM: We assessed comparative efficacy and safety of first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor [TNF]-α) agents) biologic therapy for moderate-severe CD, through a systematic review and network meta-analysis, and appraised quality of evidence (QoE) using the Grading of…

Read More

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.

Related Articles Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. Inflamm Bowel Dis. 2018 Jun 15;: Authors: Bossuyt P, Baert F, D’Heygere F, Nakad A, Reenaers C, Fontaine F, Franchimont D, Dewit O, Van Hootegem P, Vanden Branden S, Lambrecht G, Ferrante M, Belgian IBD Research and Development Group Abstract Background: Golimumab (GOL) is registered for moderate to severely active ulcerative colitis (UC). Data on the use of GOL in daily clinical practice are limited.…

Read More

A Multidisciplinary Approach to Biopsychosocial Care for Adults With Inflammatory Bowel Disease: A Pilot Study.

Related Articles A Multidisciplinary Approach to Biopsychosocial Care for Adults With Inflammatory Bowel Disease: A Pilot Study. Inflamm Bowel Dis. 2018 Jun 15;: Authors: Lee CK, Melmed GY, Mann A, Danovitch I, Hedrick R, McGovern DPB, Targan S, Shih D, Vasiliauskas E, IsHak WW, Feldman E Abstract Background: This study reports on the logistics and feasibility of a novel multidisciplinary approach to biopsychosocial care at a tertiary adult inflammatory bowel disease (IBD) center. Methods: Consecutive patients referred for a new IBD consultation completed the following self-assessments: the Short Form-12, the…

Read More

Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: A pilot study.

Related Articles Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: A pilot study. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Rowan CR, Keegan D, Byrne K, Cullen G, Mulcahy HE, Sheridan J, Ryan EJ, de Vries A, D’Haens G, Doherty GA Abstract BACKGROUND: Ustekinumab (USK) is licenced for intravenous induction and subcutaneous (S/C) maintenance in Crohn’s disease. AIM: To evaluate ustekinumab trough concentrations and clinical response with exclusive subcutaneous ustekinumab induction. METHODS: Patients with Crohn’s disease who initiated treatment with subcutaneous…

Read More

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease.

Related Articles An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V Abstract BACKGROUND: Fibrotic stricture is a common complication of Crohn’s disease (CD) affecting approximately half of all patients. No specific…

Read More

Review article: pathogenesis of Crohn’s perianal fistula-understanding factors impacting on success and failure of treatment strategies.

Related Articles Review article: pathogenesis of Crohn’s perianal fistula-understanding factors impacting on success and failure of treatment strategies. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Tozer PJ, Lung P, Lobo AJ, Sebastian S, Brown SR, Hart AL, Fearnhead N, of ENiGMA Collaboration Abstract BACKGROUND: Evidence from groups who have studied fistula aetiology and extrapolation from interventional studies supports a multifactorial hypothesis of Crohn’s perianal fistula, with several pathophysiological elements that may contribute to fistula formation, persistence and resistance to treatment. AIM: An evidence synthesis of current understanding of pathophysiological factors…

Read More

Sperm DNA Integrity is Unaffected by Thiopurine Treatment in Men with Inflammatory Bowel Disease.

Related Articles Sperm DNA Integrity is Unaffected by Thiopurine Treatment in Men with Inflammatory Bowel Disease. J Crohns Colitis. 2018 Jun 16;: Authors: Grosen A, Nersting J, Bungum M, Christensen LA, Schmiegelow K, Spanò M, Julsgaard M, Cordelli E, Leter G, Larsen PB, Hvas CL, Kelsen J Abstract Background & Aims: Sperm DNA integrity, concentration and motility are suspected to be altered by thiopurines (azathioprine (AZA) and 6-mercaptopurine (6-MP)). We investigated the impact of thiopurines on semen quality in men with inflammatory bowel disease (IBD) by a comprehensive panel of…

Read More

Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.

Related Articles Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. J Crohns Colitis. 2018 Jun 18;: Authors: Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C Abstract Background and Aims: To evaluate safety and efficacy for 3 additional years of subcutaneous golimumab maintenance in patients with moderately-to-severely active ulcerative colitis. Methods: The PURSUIT-maintenance long-term extension enrolled patients who had completed placebo or golimumab 50 mg or…

Read More
<< Go Back